Cansino Biologics Inc. (688185.SH) announced that its inhaled tuberculosis vaccine (adenovirus type 5 vector) (referred to as the "inhaled TB booster vaccine") recently commenced Phase I clinical trials in Indonesia, with the first subject successfully enrolled. The Phase I trial, conducted in Indonesia, aims to evaluate the safety and immunogenicity of a single dose of the inhaled TB vaccine (adenovirus type 5 vector) in adults aged 18–49.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments